Hyperalgesic priming is restricted to isolectin B4-positive nociceptors.
We have previously described a rat model for the contribution of neuroplastic changes in nociceptors to the transition from acute to chronic pain. In this model a prior injury activates protein kinase C epsilon (PKCepsilon), inducing a chronic state characterized by marked prolongation of the hyperalgesia induced by inflammatory cytokines, prototypically prostaglandin E(2) (PGE(2)), referred to as hyperalgesic priming. In this study we evaluated the population of nociceptors involved in priming, by lesioning isolectin B4-positive (IB4(+)) nociceptors with intrathecal administration of a selective neurotoxin, IB4-saporin. To confirm that the remaining, TrkA(+)/IB4(-), nociceptors are still functional, we evaluated if nerve growth factor (NGF) induced hyperalgesia. While pretreatment with IB4-saporin eliminated the acute mechanical hyperalgesia induced by glia-derived neurotrophic factor (GDNF), NGF and PsiepsilonRACK, a highly selective activator of PKCepsilon, induced robust hyperalgesia. After injection of NGF, GDNF or PsiepsilonRACK, at a time at which hyperalgesia induced by PGE(2) is markedly prolonged (hyperalgesic priming) in control rats, in IB4-saporin-pretreated rats PGE(2) failed to produce this prolonged hyperalgesia. Thus, while PKCepsilon is present in most dorsal root ganglion neurons, where it can contribute to acute mechanical hyperalgesia, priming is restricted to IB4(+)-nociceptors, including those that are TrkA(+). While PKCepsilon activation can induce acute hyperalgesia in the IB4(+) population, it fails to induce priming. We suggest that hyperalgesic priming occurs only in IB4(+) nociceptors, and that in the peripheral terminals of nociceptors separate intracellular pools of PKCepsilon mediate nociceptor sensitization and the induction of hyperalgesic priming.
Joseph
E K
EK
Division of Neuroscience, Departments of Medicine and Oral & Maxillofacial Surgery, University of California, San Francisco, CA 94143, USA.
Levine
J D
JD
D000818:Animals; D015232:Dinoprostone / Q000633:toxicity; D004789:Enzyme Activation / Q000187:drug effects; D005727:Ganglia, Spinal / Q000473:pathology; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000502:physiology; D006023:Glycoproteins / Q000032:analysis* / Q000378:metabolism; D006930:Hyperalgesia / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology; D007278:Injections, Spinal; D037102:Lectins / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism / Q000633:toxicity; D008297:Male; D009411:Nerve Endings / Q000502:physiology; D020932:Nerve Growth Factor / Q000633:toxicity; D009474:Neurons / Q000187:drug effects; D009498:Neurotoxins / Q000008:administration & dosage / Q000633:toxicity; D009619:Nociceptors / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D009842:Oligopeptides / Q000633:toxicity; D037121:Plant Lectins / Q000378:metabolism*; D051744:Protein Kinase C-epsilon / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D020917:Receptor, trkA / Q000502:physiology; D054789:Ribosome Inactivating Proteins, Type 1 / Q000008:administration & dosage / Q000633:toxicity; D000076985:Saporins; D013314:Stress, Mechanical; D053675:Versicans
D051100:Glial Cell Line-Derived Neurotrophic Factor; D006023:Glycoproteins; C045475:Griffonia simplicifolia lectins; C477271:His-Asp-Ala-Pro-Ile-Gly-Tyr-Asp; C496198:IB4-saporin conjugate; D037102:Lectins; D009498:Neurotoxins; D009842:Oligopeptides; D037121:Plant Lectins; D054789:Ribosome Inactivating Proteins, Type 1; C508324:Vcan protein, rat; D053675:Versicans; D020932:Nerve Growth Factor; D020917:Receptor, trkA; D051744:Protein Kinase C-epsilon; D000076985:Saporins; D015232:Dinoprostone
J Neurosci. 2006 Jul 5;26(27):7281-92
16822986
Neuroscience. 1993 May;54(2):545-51
7687755
Neuron. 1999 Sep;24(1):253-60
10677042
Neuron. 2005 Sep 15;47(6):787-93
16157274
J Neurosci. 2008 Aug 6;28(32):7936-44
18685019
Eur J Neurosci. 2005 Jun;21(12):3387-94
16026476
Brain Res Dev Brain Res. 1992 Jul 24;68(1):103-9
1521316
Pain. 2003 Sep;105(1-2):143-50
14499430
Cell. 2009 Oct 16;139(2):267-84
19837031
Neuroscience. 2010 Mar 10;166(1):107-21
20006678
Pain. 2007 Nov;132(1-2):67-73
17350763
J Neurosci. 2002 May 15;22(10):4057-65
12019325
Neurosci Lett. 1993 Apr 30;153(2):215-8
8100992
J Biol Chem. 1995 Dec 15;270(50):30134-40
8530420
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):18-26
11687273
Neuroscience. 2010 Feb 3;165(3):896-901
19931357
Neuron. 1999 Jul;23(3):617-24
10433272
J Neurosci. 2005 Jun 29;25(26):6119-26
15987941
J Pain. 2006 Dec;7(12):884-91
17157774
J Neurosci. 2000 Jun 15;20(12):4680-5
10844037
J Biol Chem. 2002 Apr 19;277(16):13375-8
11884385
Neuroscience. 2003;120(1):219-26
12849754
Neuroscience. 2006 Feb;137(3):949-60
16298080
J Pain. 2008 May;9(5):463-72
18359667
Eur J Neurosci. 2008 Jul;28(1):12-9
18616564
Annu Rev Physiol. 2002;64:407-29
11826274
Trends Neurosci. 2009 Dec;32(12):611-8
19781793